Skip to main content
Paul Yang, MD, Ophthalmology, Portland, OR

PaulYangMDPhD

Ophthalmology Portland, OR

Cataract Related, Retinal Disease, Uveitis

Associate Professor, Ophthalmic Genetics & Ocular Immunology

Dr. Yang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Yang's full profile

Already have an account?

  • Office

    545 SW Campus Dr
    Portland, OR 97239
    Phone+1 503-494-8311

Education & Training

  • Oregon Health  Science University Hospital
    Oregon Health Science University HospitalFellowship, Ophthalmic Genetics and Inherited Retinal Degeneration, 2012 - 2013
  • Massachusetts Eye and Ear Infirmary/Harvard Medical School
    Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolFellowship, Ocular Immunology/Uveitis, 2011 - 2012
  • University of Utah Health
    University of Utah HealthFellowship, Surgical Retina and Vitreous, 2010 - 2011
  • University of Utah Health
    University of Utah HealthResidency, Ophthalmology, 2007 - 2008
  • University of Utah Health
    University of Utah HealthInternship, Internal Medicine, 2006 - 2007
  • Geisel School of Medicine at Dartmouth
    Geisel School of Medicine at DartmouthClass of 2006
  • Dartmouth
    DartmouthPhD, Neurophysiology , 1998 - 2003

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 2012 - 2025
  • MA State Medical License
    MA State Medical License 2011 - 2015
  • UT State Medical License
    UT State Medical License 2007 - 2014
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease
    SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt DiseaseDecember 12th, 2024
  • Gene Therapy Allows Teen to See Snowflakes for the First Time
    Gene Therapy Allows Teen to See Snowflakes for the First TimeApril 5th, 2023
  • Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting
    Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual MeetingMay 4th, 2022
  • Join now to see all